A new clinical trial has concluded that men with testicular cancer can receive half the amount of ... [+] chemotherapy that is typically given without any increase in the risk of the disease coming back. GettyTesticular cancer is widely known to be one of the most treatable types of cancer, with 95% of men surviving the disease long-term. Now researchers have discovered that early-stage testicular cancer can be successfully prevented from coming back using half the amount of chemotherapy that is currently recommended, hence hopefully reducing the severity and incidence of treatment-related side effects. The study, published in the journal European Urology, involved nearly 250 men with early-stage testicular cancer who were deemed to be at risk of the disease returning after surgery. The three drugs used to treat early-stage testicular cancer typically are bleomycin, etoposide and cisplatin (known collectively as BEP).

Source: Forbes January 03, 2020 04:35 UTC